Welcome

Exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. To date, three medicines discovered at Exelixis have received regulatory approval to treat different types of cancer. We are steadfast in our commitment to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients in need of new treatment options.

Stock

EXEL
May 2 2016 4:00pm EDT
4.82 +0.21
4,862,798 SHARES

FDA Approval

On April 25, 2016, the United States Food and Drug Administration approved a new medicine from Exelixis, CABOMETYX™.

View Press Release
View Investor/Analyst Webcast